Evofem Announces Padagis Will Not Seek FDA Approval to Market a Generic Version of Phexxi® Until Evofem’s Phexxi Patents Expire

Posted on by

— Padagis Determined They Will Not Challenge the Phexxi Patents — — Evofem Has Phexxi Patent Protection Through 2033 — SAN DIEGO, Sept. 27, 2023 /PRNewswire/ — Evofem Biosciences, Inc., (OTCQB: EVFM) today announced that Padagis Israel Pharmaceuticals Ltd. (Padagis) has withdrawn the…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.